| 1 |
NCT02371577 |
Withdrawn |
Evaluation of the Immune Restoration Potential Of Lenalidomide |
- Chronic Lymphocytic Leukemia (CLL)
|
|
Interventional |
Phase 2 |
- University of California, San Diego
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Immunoglobulin G level
- Treatment-emergent adverse events, including infections
- Progression free survival rate at 6 months, determined by International Working Group in CLL (iwCLL) criteria.
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT02371577 |
141671 |
Revlimid |
February 1, 2017 |
December 2018 |
December 2020 |
February 25, 2015 |
April 28, 2017 |
|
- UC San Diego Moores Cancer Center
La Jolla, California, United States
|
| 2 |
NCT02279654 |
Recruiting |
Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Ascertain the Disease Progression to AML (through calculation of product limit estimators and incidence rates) for those with transfusion dependent Low to Intermediate 1 risk MDS del 5 q and have been treated with Revlimid
- Overall Survival for patients with transfusion-dependent low to intermediate 1 risk MDS and isolated del (5q) and who have been treated with Lenalidomide
- Adverse Events
- (and 2 more...)
|
1800 |
All |
18 Years and older (Adult, Senior) |
NCT02279654 |
CC-5013-MDS-010 |
PASS MDS del5q |
December 17, 2014 |
December 31, 2021 |
December 31, 2022 |
October 31, 2014 |
November 14, 2017 |
|
- AZ Klina
Brasschaat, Belgium - AZ Sint Jan
Brugge, Belgium - Hospital Erasm - 808 Route de lennik
Brussels, Belgium - (and 164 more...)
|
| 3 |
NCT02370888 |
Recruiting |
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease |
- Leukemia, Myeloid
- Myelodysplastic Syndromes
|
|
Interventional |
Phase 1 |
- University of Florida
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of lenalidomide
- CD34+ mixed chimerism
|
24 |
Female |
18 Years and older (Adult, Senior) |
NCT02370888 |
WIRB20151509
RV-CL-AML-PI-002987 |
UF-BMT-MRD-101 |
May 16, 2016 |
May 2018 |
May 2019 |
February 25, 2015 |
August 4, 2017 |
|
- University of Florida Shands Cancer Center
Gainesville, Florida, United States
|
| 4 |
NCT02302469 |
Completed |
Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia |
- Waldenstrom Macroglobulinemia
|
|
Interventional |
Phase 1
Phase 2 |
- University Hospital, Lille
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with dose limiting toxicities (DLT) of lenalidomide as a Measure of Safety and Tolerability.
- number of patients with a response to lenalidomide
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- (and 3 more...)
|
17 |
All |
18 Years and older (Adult, Senior) |
NCT02302469 |
2008_15/0837
2008-006370-15 |
RV-WM-0426 |
March 2009 |
March 2017 |
April 2017 |
November 27, 2014 |
June 7, 2017 |
|
- Centre Hospitalier de la côte basque
Bayonne, France - Ch Clermond Ferrand
Clermond Ferrand, France - CH LENS
Lens, France - (and 4 more...)
|
| 5 |
NCT03302728 |
Not yet recruiting |
Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma |
- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell, Peripheral
- Hodgkin Lymphoma
|
- Drug: Lenalidomide 15mg
- Drug: Brentuximab Vedotin 1.8 mg/Kg
|
Interventional |
Phase 1 |
- Peter MacCallum Cancer Centre, Australia
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determination of the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended phase 2 dose (RP2D) of the combination of lenalidomide and brentuximab vedotin
- Safety profile of the combination of lenalidomide and brentuximab vedotin
- Treatment intensity.
- (and 4 more...)
|
24 |
All |
18 Years and older (Adult, Senior) |
NCT03302728 |
17/34 |
EpiBrentlen |
December 15, 2017 |
May 15, 2021 |
August 15, 2021 |
October 5, 2017 |
October 10, 2017 |
|
- Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
|
| 6 |
NCT02126553 |
Recruiting |
Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in Remission |
|
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relapse-Free Survival (RFS) With Lenalidomide Maintenance Therapy
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02126553 |
2014-0116
NCI-2014-01176 |
|
November 2014 |
November 2022 |
November 2023 |
April 30, 2014 |
February 12, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 7 |
NCT01724177 |
Active, not recruiting
Has Results |
A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma |
- Adult T-Cell Leukemia-Lymphoma
|
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR) Based on the Adult T-cell Leukemia-lymphoma (ATLL) Response Criteria and Assessed by the Efficacy-Safety Evaluation Committee (ESEC)
- Kaplan Meier Estimate of Progression Free Survival (PFS) Assessed by ESEC
- Kaplan-Meier Estimate of Time to Progression (TTP)
- (and 4 more...)
|
26 |
All |
20 Years and older (Adult, Senior) |
NCT01724177 |
CC-5013-ATLL-002 |
|
November 2012 |
November 2014 |
December 2017 |
November 9, 2012 |
March 13, 2017 |
January 5, 2016 |
- Nagoya City University Hospital
Nagoya, Aichi, Japan - National Cancer Center Hospital East
Kashiwa, Chiba, Japan - Ehime University Hospital
Toon, Ehime, Japan - (and 15 more...)
|
| 8 |
NCT02018523 |
Terminated |
Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer |
- Carcinoma, Non-Small-Cell Lung
|
|
Interventional |
Phase 1 |
- Jun Zhang
- Celgene Corporation
- Baylor College of Medicine
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival
- Number of participants with adverse events
- Change in circulating immune cells
|
7 |
All |
18 Years and older (Adult, Senior) |
NCT02018523 |
H-32774 |
|
June 2014 |
August 2016 |
August 2016 |
December 23, 2013 |
January 18, 2018 |
|
- Baylor College of Medicine
Houston, Texas, United States
|
| 9 |
NCT02155634 |
Withdrawn |
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma |
- Multiple Myeloma
- Neoplasms
- Plasma Cells
- (and 4 more...)
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Response Rate
- Time to progression (TTP)
- (and 2 more...)
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT02155634 |
CC-5013-MM-027 |
|
July 2014 |
April 2017 |
March 2021 |
June 4, 2014 |
April 10, 2018 |
|
|
| 10 |
NCT01380106 |
Unknown † |
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma |
|
- Drug: Lenalidomide 15mg
- Drug: Lenalidomide 25mg
|
Interventional |
Phase 2 |
- Boston VA Research Institute, Inc.
- Celgene Corporation
- Kansas City Veteran Affairs Medical Center
- (and 4 more...)
|
Other / Industry / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Type, frequency, severity and timing of adverse events and their relationship to combination therapy with lenalidomide plus dexamethasone.
- Duration of M-Protein response during combination therapy with Lenalidomide plus dexamethasone
- Confirmed M-Protein response
- Expression of angiogenic factors, cytokines, adhesion molecules, and myeloma biomarker expression
|
80 |
All |
18 Years and older (Adult, Senior) |
NCT01380106 |
RV-MM-PI-0345 |
|
August 2010 |
September 2016 |
December 2016 |
June 27, 2011 |
February 2, 2016 |
|
- Central Arkansas Veterans Healthcare System
Little Rock, Arkansas, United States - West Los Angeles VA Medical Center
Los Angeles, California, United States - Edward Hines Jr VA Hospital
Hines, Illinois, United States - (and 4 more...)
|
| 11 |
NCT00847639 |
Completed |
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma |
|
|
Interventional |
Phase 2 |
- Center for International Blood and Marrow Transplant Research
- National Marrow Donor Program
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine tolerability and safety profile of a maximum of 12 cycles or 12 months from first dose (which ever comes first) of lenalidomide maintenance therapy post allogeneic hematopoietic cell transplantation for high risk multiple myeloma.
- To estimate the incidences of ≥ grade 3 adverse events, graft failure, infections, treatment-related mortality (TRM) and incidence and severity of acute and chronic GVHD after initiation of lenalidomide.
- To measure the overall response and best response rates to lenalidomide maintenance therapy following allogeneic HCT.
- To determine time to disease progression and overall survival after lenalidomide.
|
30 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00847639 |
07-REV |
07-REV |
February 2009 |
January 2013 |
March 2014 |
February 19, 2009 |
April 4, 2014 |
|
- City of Hope National Medical Center
Duarte, California, United States - H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States - University of Minnesota Medical Center
Minneapolis, Minnesota, United States - (and 5 more...)
|
| 12 |
NCT01750762 |
Terminated |
Lenalidomide After Allo Transplant |
|
|
Interventional |
Phase 1 |
- Beth Israel Deaconess Medical Center
- Dana-Farber Cancer Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tolerability of lenalidomide
- Effect of lenalidomide on T-cells
- Effect of lenalidomide on disease response
- The effects of lenalidomide on time to progression
|
1 |
All |
18 Years and older (Adult, Senior) |
NCT01750762 |
12-086 |
|
December 2012 |
March 2014 |
March 2014 |
December 17, 2012 |
April 18, 2017 |
|
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
|
| 13 |
NCT02963610 |
Terminated |
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer |
- Relapsed or Refractory Solid Tumors
- Nonsmall Cell Lung Cancer
|
- Drug: Lenalidomide
- Drug: Pembrolizumab
|
Interventional |
Phase 1
Phase 2 |
- Fox Chase Cancer Center
- Merck Sharp & Dohme Corp.
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the maximum tolerated dose (MTD) of lenalidomide in combination with a fixed dose of pembrolizumab in subjects with relapsed and/or refractory solid tumors.
- To determine efficacy as measured by progression free survival (PFS) in Non-small cell lung cancer patients
- Assess antitumor activity of the combination as measured by objective response rate (ORR)
- (and 8 more...)
|
3 |
All |
18 Years and older (Adult, Senior) |
NCT02963610 |
TH-088 |
|
March 29, 2017 |
October 3, 2017 |
October 3, 2017 |
November 15, 2016 |
March 19, 2018 |
|
- Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
|
| 14 |
NCT02538965 |
Active, not recruiting |
A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia |
|
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Morphological complete response rate within a maximum of 4 cycles of treatment
- Overall Response Rate (ORR)
- Response Rate according to the modified International Work Group
- (and 9 more...)
|
17 |
All |
1 Year to 18 Years (Child, Adult) |
NCT02538965 |
CC-5013-AML-002 |
|
November 19, 2015 |
July 22, 2017 |
July 13, 2022 |
September 2, 2015 |
March 29, 2018 |
|
- Children's Hospital
Birmingham, Alabama, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 59 more...)
|
| 15 |
NCT02371590 |
Withdrawn |
Lenalidomide and Obinutuzumab for Previously Untreated CLL |
- Chronic Lymphocytic Leukemia
|
- Drug: Lenalidomide
- Drug: Obinutuzumab
|
Interventional |
Phase 2 |
- University of California, San Diego
- Celgene Corporation
- Genentech, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The incidence of dose limiting toxicity
- Complete Response Rate
- Number of patients with adverse events associated with lenalidomide-obinutuzumab
- (and 2 more...)
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT02371590 |
150342/161104 |
|
February 2018 |
December 2019 |
December 2022 |
February 25, 2015 |
February 23, 2018 |
|
- UC San Diego Moores Cancer Center
La Jolla, California, United States
|
| 16 |
NCT01861340 |
Active, not recruiting |
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma |
|
- Drug: Lenalidomide, Dexamethasone, and MEDI-551
|
Interventional |
Early Phase 1 |
- Sidney Kimmel Comprehensive Cancer Center
- MedImmune LLC
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- The effect of Lenalidomide, dexamethasone and Medi-551 on multiple myeloma cancer stem cells (CSCs).
- The safety of Medi-551 when combined with Lenalidomide and dexamethasone.
|
15 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT01861340 |
J1340
NA_00081182 |
|
May 2014 |
April 2018 |
June 2018 |
May 23, 2013 |
September 28, 2017 |
|
- The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States
|
| 17 |
NCT01750983 |
Active, not recruiting |
Ipilimumab and Lenalidomide in Advanced Cancer |
|
- Drug: Ipilimumab
- Drug: Lenalidomide
|
Interventional |
Phase 1 |
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Ipilimumab in Combination With Lenalidomide
- Dose-Limiting Toxicities (DLT) of Ipilimumab in Combination With Lenalidomide
- Tumor Response
|
101 |
All |
18 Years and older (Adult, Senior) |
NCT01750983 |
2012-0795
NCI-2013-00607 |
|
March 2013 |
March 2019 |
March 2019 |
December 17, 2012 |
July 11, 2017 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 18 |
NCT01198054 |
Terminated |
LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) |
|
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Effectivity: Duration of response with lenalidomide after conventional induction chemotherapy
- Safety and tolerability: Type and intensity of adverse events related with lenalidomide
|
4 |
All |
18 Years and older (Adult, Senior) |
NCT01198054 |
LENA-LMA-5 |
|
January 2011 |
February 2013 |
February 2013 |
September 9, 2010 |
April 7, 2014 |
|
- Hospital General de Alicante.
Alicante, Spain - Hospital Germans Trias I Pujol
Badalona, Spain - Hospital Clínico y Provincial de Barcelona
Barcelona, Spain - (and 9 more...)
|
| 19 |
NCT02225275 |
Recruiting |
Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
- Drug: Lenalidomide
- Drug: Obinutuzumab
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Genentech, Inc.
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response of Combination of Lenalidomide and Obinutuzumab
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT02225275 |
2014-0115
NCI-2015-00237 |
|
March 31, 2016 |
March 1, 2023 |
March 1, 2024 |
August 26, 2014 |
March 21, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 20 |
NCT01379274 |
Terminated |
A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes |
|
- Drug: Lenalidomide and azacitidine combination
|
Interventional |
Phase 2 |
- Rush University Medical Center
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- safety and tolerability of revlimid and azacitidine combination
|
2 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT01379274 |
MDS 2008-01 |
|
January 2011 |
November 2013 |
November 2013 |
June 23, 2011 |
November 28, 2013 |
|
- Rush University Medical Center
Chicago, Illinois, United States
|
| 21 |
NCT01057121 |
Completed
Has Results |
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma |
- AIDS-Related Kaposi Sarcoma
- Recurrent Kaposi Sarcoma
|
|
Interventional |
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose of Lenalidomide Defined as the Dose Level at Which 0/6 or 1/6 Subjects Experience Dose Limiting Toxicity (DLT) With the Next Higher Dose Having at Least 2/3 or 2/6 Subjects Encountering DLT (Phase I)
- Tumor Response Rate
- Time to Death
- (and 2 more...)
|
38 |
All |
18 Years and older (Adult, Senior) |
NCT01057121 |
NCI-2012-02923
CDR0000664131
AMC-070
U01CA121947 |
|
August 2010 |
June 2014 |
June 2014 |
January 27, 2010 |
July 21, 2016 |
July 21, 2016 |
- UCLA Center for Clinical AIDS Research and Education
Los Angeles, California, United States - University of California San Diego
San Diego, California, United States - San Francisco General Hospital
San Francisco, California, United States - (and 10 more...)
|
| 22 |
NCT02312102 |
Recruiting |
Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation |
- Myelodysplastic Syndrome
- Acute Myeloid Leukemia
|
- Drug: Lenalidomide
- Drug: Velcade
|
Interventional |
Phase 1 |
- Massachusetts General Hospital
- Celgene Corporation
- Millennium Pharmaceuticals, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of Bortezomib and Lenalidomide,
- Assess clinical efficacy in terms of the number of patients experiencing a decrease in blast percentage.
- Document the remission frequency in patients receiving up to 2 induction cycles of high-dose lenalidomide combined with Velcade.
- (and 3 more...)
|
28 |
All |
18 Years and older (Adult, Senior) |
NCT02312102 |
14-213 |
|
February 2015 |
May 2017 |
August 2019 |
December 9, 2014 |
December 21, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
|
| 23 |
NCT01593410 |
Completed |
Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma |
|
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate
- Adverse Events
- Progression Free Survival (PFS)
- (and 8 more...)
|
194 |
All |
18 Years and older (Adult, Senior) |
NCT01593410 |
CC-5013-MM-021 |
|
August 1, 2010 |
January 3, 2013 |
January 3, 2013 |
May 8, 2012 |
September 20, 2017 |
|
- 307 Hospital of Chinese PLA
Beijing, China - Peking University Third Hospital
Beijing, China - Peking Union Medical College Hospital
Beijing, China - (and 10 more...)
|
| 24 |
NCT01698801 |
Active, not recruiting
Has Results |
A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma |
|
- Drug: Lenalidomide
- Drug: dexamethasone
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate
- Time to Response
- Duration of Response
- (and 3 more...)
|
26 |
All |
20 Years and older (Adult, Senior) |
NCT01698801 |
CC-5013-MM-025 |
|
October 1, 2012 |
November 26, 2013 |
June 30, 2018 |
October 3, 2012 |
December 18, 2017 |
December 3, 2014 |
- Nagoya Daini Red Cross Hospital
Nagoya, Aichi, Japan - Nagoya City University Hospital
Nagoya, Aichi, Japan - Kameda Medical Center
Kamogawa, Chiba, Japan - (and 21 more...)
|
| 25 |
NCT01270932 |
Completed |
Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients |
- Renal Failure
- Multiple Myeloma
|
- Drug: Lenalidomide and Dexamethasone
|
Interventional |
Phase 2 |
- University Health Network, Toronto
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Serum Pharmacokinetic (PK) analysis of Study drug Lenalidomide
- Evaluable for toxicity
- Evaluable for response
- Overall and progression free survival rates which will be calculated by the method of Kaplan and Meier.
|
28 |
All |
18 Years and older (Adult, Senior) |
NCT01270932 |
RV-MM-PI-0505 |
|
November 2010 |
December 18, 2017 |
December 18, 2017 |
January 5, 2011 |
December 29, 2017 |
|
- University Health Network- Princess Margaret Hosptial
Toronto, Ontario, Canada
|
| 26 |
NCT02354313 |
Active, not recruiting |
Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients |
|
|
Interventional |
Phase 3 |
- Fondazione Italiana Linfomi ONLUS
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Overall Survival (OS)
- Disease-free survival (DFS)
- (and 5 more...)
|
300 |
All |
18 Years to 60 Years (Adult) |
NCT02354313 |
IIL-MCL0208
2009-012807-25 |
MCL0208 |
May 2010 |
December 2017 |
January 2019 |
February 3, 2015 |
February 9, 2018 |
|
- UO Ematologia Ospedale Dell'Angelo
Mestre, VE, Italy - SC Ematologia A.O.SS. Biagio e Antonio e C. Arrigo
Alessandria, Italy - AORN San G.Moscati
Avellino, Italy - (and 50 more...)
|
| 27 |
NCT01816620 |
Completed |
Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome |
|
- Drug: Lenalidomide, Dexamethasone
|
Interventional |
Phase 2 |
- Peking Union Medical College Hospital
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hematological response rate
- Neurological response rate defined by ONLS score
- response rate of critical organs
- (and 6 more...)
|
41 |
All |
18 Years and older (Adult, Senior) |
NCT01816620 |
POEMS-01 |
|
March 2014 |
October 2015 |
April 2017 |
March 22, 2013 |
April 25, 2017 |
|
- Peking Union Medical College Hospital
Beijing, Beijing, China
|
| 28 |
NCT03208218 |
Completed |
Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers |
|
- Drug: SYP-1512
- Drug: Revlimid cap
|
Interventional |
Phase 1 |
- Samyang Biopharmaceuticals Corporation
- Chungnam National University Hospital
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetics of the AUCt between SYP-1512 and Revlimid cap(25mg)
- Pharmacokinetics of the Cmax between SYP-1512 and Revlimid cap(25mg)
- Pharmacokinetics of the AUCinf SYP-1512 and Revlimid cap (25mg)
- (and 2 more...)
|
42 |
Male |
20 Years to 50 Years (Adult) |
NCT03208218 |
BIBE2016-02 |
|
August 17, 2016 |
August 25, 2016 |
October 31, 2016 |
July 5, 2017 |
July 6, 2017 |
|
|
| 29 |
NCT00910858 |
Completed
Has Results |
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes |
- Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
|
- Drug: Lenalidomide
- Drug: Recombinant human erythropoietin
|
Interventional |
Phase 1
Phase 2 |
- Celgene Corporation
- Celgene
|
Industry |
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PK Phase: Area-under-the Concentration-time Curve (AUC0-24) for Lenalidomide
- Monotherapy Phase: Area-under-the Concentration-time Curve (AUC0-5) for Lenalidomide
- PK Phase: Maximum Plasma Concentration of Lenalidomide (Cmax)
- (and 9 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT00910858 |
CC-5013-PK-002 |
|
January 2005 |
April 2006 |
May 2009 |
June 1, 2009 |
September 30, 2013 |
September 30, 2013 |
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
| 30 |
NCT02871219 |
Active, not recruiting |
Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma |
|
- Drug: Obinutuzumab
- Drug: Lenalidomide
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Genentech, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS) Rate
- Complete Response (CR) Rate
|
64 |
All |
18 Years and older (Adult, Senior) |
NCT02871219 |
2015-0464
NCI-2016-01506 |
|
December 6, 2016 |
December 2019 |
December 2020 |
August 18, 2016 |
March 21, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 31 |
NCT01703364 |
Completed |
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL |
- CLL
- Chronic Lymphocytic Leukemia
|
|
Interventional |
Phase 1
Phase 2 |
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tolerability of escalated starting dose
- Establishment of maximal tolerated dose (MTD) of Lenalidomide in combination with FR
- Time to MTD
- (and 4 more...)
|
12 |
All |
18 Years and older (Adult, Senior) |
NCT01703364 |
AGMT_CLL-9
2011-004912-43 |
|
June 2012 |
March 2015 |
October 2015 |
October 10, 2012 |
May 26, 2016 |
|
- Universitätsklinik für Innere Medizin Innsbruck, Klinische Abteilung für Hämatologie und Onkologie
Innsbruck, Tirol, Austria - Universitätsklinik der PMU Salzburg, Univ-Klinik für Innere Medizin III
Salzburg, Austria
|
| 32 |
NCT01274533 |
Completed
Has Results |
Lenalidomide in HTLV-1 Adult T-Cell Leukemia |
- Adult T Cell Leukemia/Lymphoma
|
|
Interventional |
Phase 2 |
- Columbia University
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate (CR + Cru + PR)
- Safety of Lenalidomide Monotherapy
|
4 |
All |
18 Years and older (Adult, Senior) |
NCT01274533 |
AAAE5097 |
|
December 2010 |
January 2013 |
May 2013 |
January 11, 2011 |
May 23, 2016 |
April 22, 2016 |
- Columbia University Medical Center
New York, New York, United States
|
| 33 |
NCT01996865 |
Recruiting |
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. |
|
- Drug: Lenalidomide
- Drug: Rituximab
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS) for Follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL)
- Adverse Events
- Complete response rate
- (and 6 more...)
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT01996865 |
CC-5013-NHL-008 |
MAGNIFY |
April 2, 2014 |
April 8, 2023 |
July 8, 2024 |
November 27, 2013 |
March 29, 2018 |
|
- Arizona Oncology
Tucson, Arizona, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - Sutter East Bay Hospitals
Berkeley, California, United States - (and 113 more...)
|
| 34 |
NCT02322320 |
Recruiting |
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT) |
|
|
Interventional |
Phase 3 |
- National Heart, Lung, and Blood Institute (NHLBI)
- Blood and Marrow Transplant Clinical Trials Network
- National Cancer Institute (NCI)
- National Marrow Donor Program
|
NIH / Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Compare the PFS as a time to event analysis from randomization on the BMT CTN 0702 protocol between the three randomized treatment arms as a pairwise comparison.
- Overall survival from randomization on the BMT CTN 0702 protocol
- Event-free survival from randomization on the BMT CTN 0702 protocol
- (and 2 more...)
|
450 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02322320 |
BMTCTN07LT
U01HL069294-05 |
|
March 2015 |
December 2018 |
December 2018 |
December 23, 2014 |
August 25, 2017 |
|
- Arizona Cancer Center
Tucson, Arizona, United States - City of Hope National Medical Center
Duarte, California, United States - University of California, San Diego Medical Center
La Jolla, California, United States - (and 51 more...)
|
| 35 |
NCT01342172 |
Terminated
Has Results |
Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma |
- Urinary Bladder Neoplasms
|
|
Interventional |
Phase 1
Phase 2 |
- Icahn School of Medicine at Mount Sinai
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase I: To Determine the Recommended Phase II Dose of the Combination of Gemcitabine, Cisplatin, Plus Lenalidomide
- Phase II: Progression-free Survival at 1 Year
- To Determine the Objective Response Rate to Treatment With Gemcitabine, Cisplatin, Plus Lenalidomide
- (and 4 more...)
|
9 |
All |
18 Years and older (Adult, Senior) |
NCT01342172 |
GCO 10-1339 |
|
March 2011 |
June 2013 |
June 2013 |
April 27, 2011 |
December 15, 2014 |
November 26, 2014 |
- National Cancer Institute
Bethesda, Maryland, United States - Icahn School of Medicine at Mount Sinai
New York, New York, United States - Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, United States
|
| 36 |
NCT01947309 |
Terminated |
Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide) |
|
- Drug: Revlimid (lenalidomide)
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Progression Free Survival (PFS)
- Response Rates
- Overall Survival (OS)
- (and 3 more...)
|
176 |
All |
18 Years and older (Adult, Senior) |
NCT01947309 |
NIPMS-RV-CN-001 |
|
November 2013 |
July 2016 |
September 2016 |
September 20, 2013 |
January 12, 2017 |
|
- Peking Chao-Yang Hospital
Beijing, China - Peking University People's Hospital
Beijing, China - People's Liberation Army Hospital 307
Beijing, China - (and 14 more...)
|
| 37 |
NCT02255162 |
Terminated |
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML |
- Acute Myeloid Leukemia (AML)
- Acute Myelocytic Leukemia
- Acute Myelogenous Leukemia
- (and 2 more...)
|
- Drug: Lenalidomide
- Genetic: HLA-mismatched stem-cell Microtransplantation
- Drug: Cytarabine
|
Interventional |
Phase 1 |
- Massachusetts General Hospital
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of lenalidomide after microtransplantation
- Disease Free Survival
- Overall Survival
- (and 3 more...)
|
8 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02255162 |
14-265 |
|
January 2015 |
December 2016 |
December 2016 |
October 2, 2014 |
August 18, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 38 |
NCT01718379 |
Completed |
Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality. |
- Myelodysplastic Syndromes
|
- Drug: Lenalidomide
- Drug: Epoetin beta
|
Interventional |
Phase 2 |
- Groupe Francophone des Myelodysplasies
- Celgene
- Roche Pharma AG
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Comparing the efficacy of Lenalidomide alone to Lenalidomide with Epoetin beta in transfusion-dependent ESA-resistant
- will be to assess the safety of Lenalidomide and of its combination with Epoetin beta
|
132 |
All |
18 Years and older (Adult, Senior) |
NCT01718379 |
GFM-Len-Epo-08 |
|
July 2010 |
November 2012 |
June 2016 |
October 31, 2012 |
November 8, 2016 |
|
- Hematology Dpt, Service d'Hématologie Clinique
CHU Albert Michallon, Grenoble, France - Hematology Dpt, CHU de Bicêtre
Le Kremlin-Bicêtre, Ile de France, France - Hematology Dpt, CHU Cochin
Paris, Ile de France, France - (and 45 more...)
|
| 39 |
NCT02523040 |
Recruiting |
A Study of Lenalidomide for Adult Histiocyte Disorders |
- Langerhans Cell Histiocytosis (LCH)
- Histiocytoses Erdheim-chester Disease
- Histiocytic Sarcoma (HS)
|
|
Interventional |
Phase 2 |
- Dana-Farber Cancer Institute
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate
- Progression Free Survival (PFS)
- Overall Survival
- (and 4 more...)
|
12 |
All |
18 Years and older (Adult, Senior) |
NCT02523040 |
15-197 |
|
August 2015 |
August 2018 |
August 2022 |
August 14, 2015 |
June 2, 2017 |
|
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
| 40 |
NCT02692339 |
Recruiting |
Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma |
|
- Drug: Lenalidomide
- Drug: Dexamethasone
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of Adverse events of special interest during Len/Dex therapy
- Incidence (number) of thromboembolism
- Duration of Len/Dex treatment over the course of the study
- (and 2 more...)
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT02692339 |
CC-5013-MM-028 |
PrObe-L |
February 25, 2016 |
September 29, 2023 |
September 29, 2023 |
February 26, 2016 |
March 6, 2018 |
|
- Hospital Garcia Orta, E.P.E.
Almada, Portugal - Hospital Professor Doutor Fernando Fonseca, E.P.E.
Amadora, Portugal - Hospital Central de Faro
Faro, Portugal - (and 9 more...)
|
| 41 |
NCT01723839 |
Active, not recruiting |
Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide |
- Chronic Lymphocytic Leukemia (CLL)
|
- Drug: Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide
|
Interventional |
Phase 2 |
- Hackensack University Medical Center
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete Response
- Overall Response Rate
|
54 |
All |
18 Years and older (Adult, Senior) |
NCT01723839 |
Pro00002262 RV-CLL-PI-0530 |
FCR |
February 22, 2012 |
January 12, 2015 |
August 2018 |
November 8, 2012 |
August 10, 2017 |
|
- John Theurer Cancer Center at HackensackUMC
Hackensack, New Jersey, United States
|
| 42 |
NCT01582776 |
Active, not recruiting |
Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma |
- Follicular Lymphoma Patients (Phase IB)
- Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)
|
- Drug: Lenalidomide and GA101
|
Interventional |
Phase 1
Phase 2 |
- The Lymphoma Academic Research Organisation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase I part: Determination of the recommended dose of lenalidomide in combination with fixed doses of GA101
- Phase II part: Overall Response Rate (CR+CRu+PR) after 6 cycles
- Overall survival (OS)
- (and 6 more...)
|
317 |
All |
18 Years and older (Adult, Senior) |
NCT01582776 |
GALEN |
|
October 2012 |
July 2018 |
March 2022 |
April 23, 2012 |
March 7, 2018 |
|
- ZNA Stuivenberg
Antwerpen, Belgium - A.Z. Sint Jan AV
Bruges, Belgium - institut Jules Bordet
Bruxelles, Belgium - (and 22 more...)
|
| 43 |
NCT01169298 |
Completed |
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma |
- Adult T-cell Leukemia-Lymphoma
- Peripheral T-cell Lymphoma
|
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The safety of lenalidomide evaluated based on the severity of adverse events and their causality
- Response
- PK-Time to Maximum Plasma Concentration (Tmax)
- (and 7 more...)
|
13 |
All |
20 Years and older (Adult, Senior) |
NCT01169298 |
CC-5013-ATLL-001 |
|
July 2010 |
December 2013 |
December 2013 |
July 26, 2010 |
October 31, 2016 |
|
- National Kyusyu Cancer Center
Fukuoka, Japan - Imamura Bun-in Hospital
Kagoshima, Japan - Kumamoto University Hospital
Kumamoto, Japan - (and 3 more...)
|
| 44 |
NCT03232307 |
Not yet recruiting |
Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL) |
- Hematopoietic/Lymphoid Cancer
- Mantle Cell Lymphoma
|
- Drug: Ibrutinib
- Drug: Rituximab
- Drug: Lenalidomide
- Drug: Dexamethasone Sodium Sulfate
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Celgene
- Janssen Scientific Affairs, LLC
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR) at 4 Months of Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL)
- Summary of Adverse Events of Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL)
|
40 |
All |
66 Years and older (Senior) |
NCT03232307 |
2016-0280 |
|
April 2018 |
April 2023 |
April 2024 |
July 27, 2017 |
January 24, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 45 |
NCT01919619 |
Recruiting |
Lenalidomide and Ipilimumab Post Allo or Auto Stem Cell Transplantation (SCT) |
- Blood And Marrow Transplantation
- Leukemia
- Lymphoma
|
- Drug: Lenalidomide
- Drug: Ipilimumab
|
Interventional |
Early Phase 1 |
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
40 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT01919619 |
2012-0947
NCI-2013-02213 |
|
November 2013 |
November 2019 |
November 2019 |
August 9, 2013 |
December 12, 2017 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 46 |
NCT01264315 |
Recruiting |
Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant |
|
|
Interventional |
Phase 2 |
- Fondazione Neoplasie Sangue Onlus
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Lenalidomide toxicity and tolerability after allografting
- Lenalidomide efficacy
- Overall survival
- (and 4 more...)
|
53 |
All |
18 Years to 65 Years (Adult) |
NCT01264315 |
RV-MM-GITMO-413
2008-004529-41 |
|
September 2008 |
December 2012 |
December 2017 |
December 21, 2010 |
September 6, 2017 |
|
- A.O.U. San Giovanni Battista
Torino, Italy
|
| 47 |
NCT01766583 |
Completed |
A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma |
- Relapsed/Refractory B-cell Lymphoma
|
- Drug: CC-292 + lenalidomide
|
Interventional |
Phase 1 |
- The Lymphoma Academic Research Organisation
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determination of the recommended dose of CC-292 and lenalidomide in patients with relapsed/refractory B-cell lymphoma
- preliminary efficacy signals of the CC-292 + Lenalidomide combination
- Observed maximum plasma concentration
- (and 6 more...)
|
18 |
All |
18 Years and older (Adult, Senior) |
NCT01766583 |
CLEAR |
CLEAR |
February 2013 |
November 2014 |
January 2018 |
January 11, 2013 |
March 7, 2018 |
|
- Hopital henri mondor
Créteil, France - CHU de Lille
Lille, France - Institut Paoli Calmette
Marseille, France - (and 3 more...)
|
| 48 |
NCT01352338 |
Completed |
Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT) |
|
- Drug: Lenalidomide, endoxan, prednisone
- Drug: lenalidomide, endoxan, prednisone
|
Interventional |
Phase 1
Phase 2 |
- UMC Utrecht
- Celgene Corporation
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1 Revlimid, Endoxan, Prednisone Evaluation After prior revlimid Treatment (REPEAT)
- phase 1 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT)
- phase 2 part of the study Revlimid, Endoxan, Prednison Evaluation After prior revlimid Treatment (REPEAT)
|
82 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT01352338 |
RV-MM-PI-0630 |
REPEAT |
August 2011 |
November 2014 |
February 2016 |
May 11, 2011 |
February 26, 2016 |
|
- Antonius Ziekenhuis Nieuwegein
Nieuwegein, Utrecht, Netherlands - VU Medical Center
Amsterdam, Netherlands - UMC Utrecht
Utrecht, Netherlands
|
| 49 |
NCT00751296 |
Terminated
Has Results |
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL) |
- Chronic Lymphocytic Leukaemia
|
|
Interventional |
Phase 2 |
- University Health Network, Toronto
- Celgene
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To Assess the Efficacy (Response Rate) of Oral Lenalidomide in the Treatment of Patients With Symptomatic, Previously Untreated, Chronic Lymphocytic Leukemia (CLL)
- Percentage of Participants With Progression-free Survival (PFS) and Overall Survival (OS).
|
27 |
All |
18 Years and older (Adult, Senior) |
NCT00751296 |
Rev-06-0099
RV-CLL-PI-0099 |
Rev-CLL |
August 2006 |
April 2014 |
April 2014 |
September 11, 2008 |
June 16, 2016 |
May 12, 2016 |
- University Health Network - Princess Margaret Cancer Centre
Toronto, Ontario, Canada
|
| 50 |
NCT01460940 |
Completed
Has Results |
A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma |
- Adult Lymphocyte Depletion Hodgkin Lymphoma
- Adult Lymphocyte Predominant Hodgkin Lymphoma
- Adult Mixed Cellularity Hodgkin Lymphoma
- (and 3 more...)
|
- Drug: panobinostat
- Drug: lenalidomide
|
Interventional |
Phase 2 |
- Ohio State University Comprehensive Cancer Center
- Celgene
- Novartis
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the Overall Response Rate (ORR), Including Complete Responses (CR) and Partial Responses (PR)
- Assess the Safety and Tolerability of Combined Lenalidomide and Panobinostat in Patients With Previously Treated Hodgkin's Lymphoma.
- Progression-free Survival in Patients With Previously Treated Hodgkin's Lymphoma Receiving Combined Lenalidomide and Panobinostat
|
24 |
All |
18 Years and older (Adult, Senior) |
NCT01460940 |
OSU-10049
NCI-2011-03323 |
|
October 13, 2011 |
November 16, 2016 |
November 16, 2016 |
October 27, 2011 |
November 14, 2017 |
March 14, 2017 |
- Washington University
Saint Louis, Missouri, United States - The Ohio State University Medical Center
Columbus, Ohio, United States
|
Create an RSS feed from your search for:
Download the search results for: